Navigation Links
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:9/24/2008

ts travel in the circulatory system to the brain and muscles causing the nerves to become over-stimulated which leads to massive convulsions and death in severe cases.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) -- a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) -- a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) -- a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve

agents

-- RypVax(TM) -- a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit http://www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
(Date:9/16/2014)... NEW YORK, NY (September 16, 2014) The ... received the 2014 Higher Education Excellence in Diversity ... oldest and largest diversity-focused publication in higher education. ... national honor recognizing U.S. colleges and universities that ... will be featured along with 82 other recipients ...
(Date:9/16/2014)... Orange, NJ. September 16, 2014. Kessler Foundation researchers ... slowed processing speed in the executive deficits found ... slowed processing speed account for executive deficits in ... neuroimaging," was published online ahead of print on ... The authors are Victoria Leavitt, PhD, of ...
(Date:9/16/2014)... judges are the unwitting focus of some of Australia,s ... to improve their performance in competition, thanks to a ... Dr Daniel Greenwood, from QUT,s Institute of Health and ... Sport Centre of Excellence for Applied Sport Science Research, ... such as cricket, long jump, triple jump and pole ...
(Date:9/16/2014)... San Francisco, September 15, 2014 For patients with ... and stereotactic ablative radiation (SABR) may be a ... surgery that may not otherwise be an option, ... Society for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. ... for individuals with pancreatic ductal adenocarcinoma (PDA), the ...
(Date:9/16/2014)... be presented at the ESMO 2014 Congress will be ... (CEST) to give you a first glimpse of what ... under the leading theme Precision Medicine in Cancer Care. ... therapy is now possible for an increasing number of ... towards a common goal --improved patient outcomes. This is ...
Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
... School of Medicine has helped confirm the reliability of ... individual's genetic makeup. ,The Stanford group was ... the genetic test can identify patients who are at ... infection. That means high-risk patients could be directed toward ...
... A report released by the Australian Institute of Health ... in Queensland. Nearly 20 to 50% of the population ... to be relying on anti-depressants heavily. ... affair in Queensland where nearly 11,500 prescriptions for anti ...
... today has become the number one killer. More so, related ... occupational Hazard// with millions of people running the risk of ... fibers and second hand smoker are the major causes of ... from exposure to benzene from the dye, drugs, pesticides and ...
... the world. There is also a rise of alcohol abuse ... women says that in women cognitive problems develop faster in ... subject to physical changes in the brain more rapidly than ... at the research institute RTI at the university in Baltimore ...
... Institute of Medicine released a report recommending nutrition ... school environment, such as a la carte cafeteria ... Dairy Council (NDC) applauds the overall recommendations outlined ... nonfat and low-fat dairy products, fruits, vegetables and ...
... An international research team, led by investigators from the ... Institute (DFCI), has found// a new way that some ... drugs like Iressa and Tarceva. Their report, which will ... online release, describes a totally new resistance mechanism that ...
Cached Medicine News:Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 2Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 3Health News:Today Cancer is the Deadliest Killer 2Health News:Alcoholism Develops Cognitive Problems in Women 2Health News:National Academy of Sciences' Institute of Medicine Report Calls for More Dairy Foods at School 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 3
... Innovations' Instrument Manager (IM) is an instrument ... system that enables laboratories to work more ... as a data management solution that stands ... information system, filling those important gaps in ...
... These color vision tests have been designed ... the type and estimating the grade of ... measure Red, Green, Blue, Yellow. They provide ... deficiencies. Screening is accomplished using the initial ...
... sets are designed to indicate color deficiency ... is used to separate Medium and Strong ... test is much more difficult and is ... Both of these tests provide basic ...
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Medicine Products: